Suscribirse

Exercise Echocardiography for Risk Stratification in Unexplained Dyspnea: The Incremental Value of the Mean Pulmonary Artery Pressure/Slope - 01/10/25

Doi : 10.1016/j.echo.2025.06.007 
Maarten Falter, MD a, b, c, Youri Bekhuis, MD a, b, c, d, Wouter L’Hoyes, MD e, f, Mauricio Milani, MD, PhD a, g, h, Sarah Hoedemakers, MD a, b, Lucie Soens, MD i, j, Sara Moura-Ferreira, MD a, b, Sebastiaan Dhont, MD b, k, Rik Pauwels, MD a, b, c, d, Annemie Jacobs, MD e, Stephanie De Schutter, MD l, m, Boris Delpire, MD a, b, d, Johan Verbeeck, PhD n, Jan Stassen, MD, PhD a, b, Andreas B. Gevaert, MD, PhD l, m, Philippe Debonnaire, MD, PhD e, Alexander Van de Bruaene, MD, PhD c, d, Philippe B. Bertrand, MD, PhD b, k, Lieven Herbots, MD, PhD a, b, Ruta Jasaityte, MD, PhD a, b, Frederik H. Verbrugge, MD, PhD, MSc i, j, Guido Claessen, MD, PhD a, b, c, Jan Verwerft, MD a, b, ⁎
a Department of Cardiology and Jessa & Science, Jessa Hospital, Hasselt, Belgium 
b Faculty of Medicine and Life Sciences/LCRC, UHasselt, Diepenbeek, Belgium 
c Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium 
d Department of Cardiovascular Diseases, UZ Leuven, Leuven, Belgium 
e Department of Cardiology, Sint-Jan Hospital, Bruges, Belgium 
f Department of Cardiology, Imelda Hospital, Bonheiden, Belgium 
g Faculty of Rehabilitation Sciences, Rehabilitation Research Center, UHasselt, Diepenbeek, Belgium 
h Health Sciences and Technologies Graduate Program, University of Brasilia, Brasilia, Brazil 
i Centre for Cardiovascular Diseases, University Hospital Brussels, Jette, Belgium 
j Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium 
k Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium 
l Research Group Cardiovascular Diseases, GENCOR Department, University of Antwerp, Antwerp, Belgium 
m Department of Cardiology, Antwerp University Hospital, Edegem, Belgium 
n DSI, I-Biostat, UHasselt, Diepenbeek, Belgium 

∗Reprint requests: Jan Verwerft, MD, Heart Center, Jessa Hospital, Stadsomvaart 11, Hasselt 3500, Belgium.Heart CenterJessa HospitalStadsomvaart 11Hasselt3500Belgium

Abstract

Background

Patients with unexplained dyspnea and an elevated mean pulmonary artery pressure (mPAP)/cardiac output (CO) slope on invasive hemodynamic assessment during exercise have worse clinical outcomes. The aim of this study was to evaluate the incremental prognostic value of the noninvasive mPAP/CO slope in addition to heart failure with preserved ejection fraction (HFpEF) probability scores and diastolic stress testing in patients with unexplained dyspnea.

Methods

In a multicenter cohort study involving six Belgian dyspnea clinics, patients with unexplained dyspnea underwent exercise echocardiography for mPAP/CO slope assessment. Positive HFpEF scores were defined as HFA-PEFF (Heart Failure Association pretest probability echocardiography, functional testing, final diagnosis) score ≥ 5 and H2FPEF (heavy, hypertensive, atrial fibrillation, pulmonary hypertension, elder, filling pressure) score ≥ 6. The outcome evaluated was a composite of all-cause mortality or heart failure hospitalization.

Results

Among 2,452 patients (mean age, 63 ± 15 years; 53% women), mPAP/CO slope > 3.5 mm Hg · L−1 · min−1 best predicted adverse outcomes. The prognostic value of the mPAP/CO slope was greater in patients with negative HFpEF scores than in those with positive scores (interaction P = .02). The mPAP/CO slope remained independently prognostic after adjustment for N-terminal pro–B-type natriuretic peptide (hazard ratio [HR], 2.26; 95% CI, 1.33-3.82) and for HFpEF scores and diastolic stress testing (HR, 1.99; 95% CI, 1.37-2.88), whereas exercise tricuspid regurgitant velocity did not. Both HFpEF score–negative patients with slope > 3.5 mm Hg · L−1 · min−1 (HR, 2.99; 95% CI, 1.81-4.95) and HFpEF score–positive patients (HR, 6.29; 95% CI, 4.25-9.31) showed significantly higher risk compared with HFpEF score–negative patients with slope ≤ 3.5 mm Hg · L−1 · min−1.

Conclusions

The mPAP/CO slope, unlike exercise tricuspid regurgitant velocity, adds prognostic value beyond natriuretic peptides, HFpEF scores, and diastolic stress testing, identifying high-risk patients with exercise-induced hemodynamic abnormalities who may benefit from invasive confirmation and closer follow-up.

El texto completo de este artículo está disponible en PDF.

Central Illustration

Kaplan-Meier curves demonstrating time to the composite outcome (all-cause mortality or heart failure hospitalization). Consecutive patients with unexplained dyspnea were assessed using the HFpEF scores and exercised echocardiography at six dyspnea clinics in Belgium. Patients were categorized into three groups: (1) HFpEF score positive (HFA-PEFF score ≥ 5 or H2FPEF score ≥ 6; red), (2) HFpEF score negative with elevated mPAP/CO slope (>3.5 mm Hg · L−1 · min−1; blue), and (3) HFpEF score negative with normal mPAP/CO slope (≤3.5 mm Hg · L−1 · min−1; green; reference group).



Central Illustration : 

Kaplan-Meier curves demonstrating time to the composite outcome (all-cause mortality or heart failure hospitalization). Consecutive patients with unexplained dyspnea were assessed using the HFpEF scores and exercised echocardiography at six dyspnea clinics in Belgium. Patients were categorized into three groups: (1) HFpEF score positive (HFA-PEFF score ≥ 5 or H2FPEF score ≥ 6; red), (2) HFpEF score negative with elevated mPAP/CO slope (>3.5 mm Hg · L−1 · min−1; blue), and (3) HFpEF score negative with normal mPAP/CO slope (≤3.5 mm Hg · L−1 · min−1; green; reference group).


Central IllustrationKaplan-Meier curves demonstrating time to the composite outcome (all-cause mortality or heart failure hospitalization). Consecutive patients with unexplained dyspnea were assessed using the HFpEF scores and exercised echocardiography at six dyspnea clinics in Belgium. Patients were categorized into three groups: (1) HFpEF score positive (HFA-PEFF score ≥ 5 or H2FPEF score ≥ 6; red), (2) HFpEF score negative with elevated mPAP/CO slope (>3.5 mm Hg · L−1 · min−1; blue), and (3) HFpEF score negative with normal mPAP/CO slope (≤3.5 mm Hg · L−1 · min−1; green; reference group).

El texto completo de este artículo está disponible en PDF.

Highlights

•
mPAP/CO slope > 3.5 predicts 3-4 times higher risk for death or HF hospitalization.
•
Adds prognostic value beyond NT-proBNP, HFpEF scores, and DSTs.
•
Flags high-risk early HFpEF group missed by scores; invasive confirmation warranted.
•
Two-thirds of patients had low scores and mPAP/CO slopes and low event rates.
•
The results support exercise echo in dyspnea clinics for better risk stratification.

El texto completo de este artículo está disponible en PDF.

Keywords : mPAP/CO slope, Heart failure with preserved ejection fraction, Dyspnea, Echocardiography, Exercise testing

Abbreviations : CO, COPD, CPET, CPETecho, DST, exE/e′, exTRV, FEV1, H2FPEF, HFA-PEFF, HFpEF, HR, ICC, IQR, mPAP, NT-proBNP, RAP, RER, SpO2, TR, TRG, TRV, V̇co2, V̇e, V̇o2


Esquema


 Drs. Falter and Bekhuis have received funding through the Flanders Research Foundation FWO (file number 1SE1222N and T004420N, respectively). Dr Gevaert is supported by the Belgian Heart Foundation (Dumont Prize) and the University of Antwerp (BOF DOCPRO4 51265). Dr. Dhont is supported by Research Foundation Flanders (Strategic Basic Research 1SH5O24N).
 Drs. Falter and Bekhuis contributed equally to this work as joint first authors.
 Drs. Claessen and Verwerft contributed equally to this work as joint senior authors.


© 2025  American Society of Echocardiography. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 38 - N° 10

P. 875-889 - octobre 2025 Regresar al número
Artículo precedente Artículo precedente
  • Information for Readers
| Artículo siguiente Artículo siguiente
  • Lung Ultrasound Density Score Index Performed With Cardiopulmonary Exercise Echocardiography Testing Is Associated With Impaired Exercise Capacity
  • Charles E. Luoma, Kathryn F. Larson, Joshua R. Smith, Jessica A. Narum, Christopher G. Scott, Alexander T. Lee, Meir Tabi, Brandon M. Wiley

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.